Author of

• 25520

  +

  Poster Display session (Friday) (ID 65)

  • Event: ELCC 2018
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1

  • 25403

    +

    203P - Combined pulmonary metastasectomy and chemotherapy in patients with colorectal lung metastases and concurrent extrapulmonary disease (ID 282)

    12:50 - 12:50  |  Author(s): A. Abo Bakr
    • Abstract

    Background:
    Lung metastases from colorectal cancer (CRC) with the presence of concurrent extra-pulmonary disease is considered a very poor prognosis. Chemotherapy was the only advised treatment. Nowadays with the evolution in surgical oncology techniques, imaging and medical oncology treatment, a better management is present for stage IV colorectal cancer with a prolonged overall survival. We aim to evaluate the benefit of adding surgical resection to chemotherapy in patients with colorectal lung metastasis and extra-pulmonary diseases.
    
    Methods:
    We extracted the data of 1423 colorectal cancer patients with pulmonary and extra-pulmonary metastases from 2010 to 2013, using SEER database. Ninety-nine (7%) patients had combined chemotherapy and pulmonary metastasectomy, while 1324 (93%) of them received chemotherapy only.
    
    Results:
    Patients who received combination of chemotherapy and pulmonary metastasectomy had better 1-year survival rates (83.5%), compared to those who received chemotherapy only (68.3%). We observed a statistically significant difference between the two modalities in white patients, patients aged between 40 to 59 years, tumors arising in sigmoid colon or rectum, patients with elevated CEA levels, and those with metastasis to the lungs only or both lung and liver.Table: (Abstract: 203P)

    Variables	Combined Therapy	Chemotherapy	p value (difference in modalities	p value (difference in combined therapy)
    Sex
    Male	79.4%	66.6%	0.007**	0.399
    Female	87.1%	70.6%	<0.001**
    Age
    20–39	66.7%	77.8%	0.219	0.201
    40–59	89.7%	74.2%	<0.001**
    60–79	73.0%	66.2%	0.159
    ≥80	100%	43.2%	0.221
    Race
    White	86.7%	69.3%	<0.001**	0.687
    Black	74.3%	65.4%	0.061
    Others	77.9%	66.1%	0.036**
    Primary Site
    Cecum	76.1%	69.0%	0.750	0.003*
    Ascending Colon	70.0%	58.0%	0.401
    Hepatic	0%	55.1%	0.361
    Flexure Transverse Colon	100%	55.5%	0.605
    Splenic Flexure	60.3%	59.2%	0.937
    Descending Colon	75.3%	64.3%	0.068
    Sigmoid Colon	85.5%	68.5%	0.002**
    Rectum	100%	74%	<0.001**
    Distant Metastasis
    Lung Only	94.5%	78.9%	0.002**	0.007*
    Lung and Liver	77.4%	64.7%	0.002**
    Lung and Brain	100%	25.3%	0.198
    Lung and Bone	50.8%	65.9%	0.783
    CEA Level
    Normal	95.7%	81.4%	0.378	0.446
    Elevated	79.9%	66.2%	<0.001**

    
    
    Conclusions:
    Combining pulmonary metastasectomy with chemotherapy in CRC patients with pulmonary and extrapulmonary metastases shows higher 1-year relative survival rates when compared to using chemotherapy alone.
    
    Clinical trial identification:
    
    
    Legal entity responsible for the study:
    Inas Uthman
    
    Funding:
    Has not received any funding
    
    Disclosure:
    All authors have declared no conflicts of interest.